HTML Microdata document

This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/chebi/
n7	http://linked.opendata.cz/resource/drugbank/company/
n28	http://linked.opendata.cz/resource/mesh/concept/
foaf	http://xmlns.com/foaf/0.1/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/wikipedia/
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/pharmgkb/
n13	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/bindingdb/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/kegg-compound/
n21	http://bio2rdf.org/drugbank:
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/pubchem-compound/
adms	http://www.w3.org/ns/adms#
n22	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/pubchem-substance/
n10	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/kegg-drug/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/drugbank/
n17	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
owl	http://www.w3.org/2002/07/owl#
n27	http://linked.opendata.cz/ontology/mesh/
n5	http://linked.opendata.cz/ontology/drugbank/
n14	http://www.drugs.com/cdi/
n6	http://linked.opendata.cz/resource/drugbank/property/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/national-drug-code-directory/
n4	http://www.rxlist.com/cgi/generic2/
n29	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdh	http://www.w3.org/2001/XMLSchema#
n25	http://linked.opendata.cz/ontology/sukl/drug/
n26	http://linked.opendata.cz/resource/atc/
n11	http://linked.opendata.cz/resource/drugbank/drug/DB00978/identifier/chemspider/

Statements

Subject Item: n2:DB00978
rdf:type: n5:Drug
n5:description: Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
n5:group: approved
n5:halfLife: 8 hours
n5:indication: For the treatment of bacterial infections of the respiratory tract (chronic bronchitis) and urinary tract, and as a pre-operative prophylactic to prevent urinary tract infection caused by: S.pneumoniae, H.influenzae, S.aureus, P.aeruginosa, E. cloacae, P. mirabilis, C. civersus, S. asprphyticus, E.coli, and K.pneumoniae.
n5:manufacturer: n7:271B481C-363D-11E5-9242-09173F13E4C5
owl:sameAs: n17:DB00978 n21:DB00978
dcterms:title: Lomefloxacin
adms:identifier: n9:C07078 n10:D02318 n11:3811 n12:DB00978 n13:50240373 n15:116278 n18:PA164749165 n19:Lomefloxacin n20:3948 n22:46508499 n23:0025-5501-01
n5:mechanismOfAction: Lomefloxacin is a bactericidal fluoroquinolone agent with activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of lomefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited.
n5:packager: n7:271B481A-363D-11E5-9242-09173F13E4C5 n7:271B481B-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination: The urinary excretion of lomefloxacin was virtually complete within 72 hours after cessation of dosing, with approximately 65% of the dose being recovered as parent drug and 9% as its glucuronide metabolite.
n5:synonym: Lomefloxacine LFLX 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid Lomefloxacino Lomefloxacinum
n5:toxicity: Adverse reactions include peripheral neuropathy, nervousness, agitation, anxiety, and phototoxic events (rash, itching, burning) due to sunlight exposure.
n5:proteinBinding: 10%
n5:salt
n5:synthesisReference: "DrugSyn.org":http://www.drugsyn.org/Lomefloxacin.htm
n27:hasConcept: n28:M0150494
foaf:page: n4:lomefloxacin.htm n14:lomefloxacin.html n29:max1249.shtml
n5:IUPAC-Name: n6:271B4821-363D-11E5-9242-09173F13E4C5
n5:InChI: n6:271B4827-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula: n6:271B4826-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight: n6:271B4823-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight: n6:271B4824-363D-11E5-9242-09173F13E4C5
n5:SMILES: n6:271B4825-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility: n6:271B481F-363D-11E5-9242-09173F13E4C5 n6:271B4837-363D-11E5-9242-09173F13E4C5
n5:logP: n6:271B4839-363D-11E5-9242-09173F13E4C5 n6:271B481D-363D-11E5-9242-09173F13E4C5 n6:271B4820-363D-11E5-9242-09173F13E4C5
n5:logS: n6:271B481E-363D-11E5-9242-09173F13E4C5
n25:hasATCCode: n26:J01MA07 n26:S01AE04
n5:H-Bond-Acceptor-Count: n6:271B482D-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count: n6:271B482E-363D-11E5-9242-09173F13E4C5
n5:InChIKey: n6:271B4828-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-: n6:271B4829-363D-11E5-9242-09173F13E4C5
n5:Polarizability: n6:271B482B-363D-11E5-9242-09173F13E4C5
n5:Refractivity: n6:271B482A-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count: n6:271B482C-363D-11E5-9242-09173F13E4C5
n5:absorption: Rapid and nearly complete with approximately 95% to 98% of a single oral dose being absorbed.
n5:affectedOrganism: Enteric bacteria and other eubacteria
n5:casRegistryNumber: 98079-51-7
n5:category
n5:clearance: * 271 mL/min/1.73 m2 [creatinine clearance of 110 mL/min/1.73 m2] * 31 mL/min/1.73 m2 [creatinine clearance of 0 mL/min/1.73 m2]
n5:Bioavailability: n6:271B4833-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter: n6:271B4835-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule: n6:271B4836-363D-11E5-9242-09173F13E4C5
n5:Melting-Point: n6:271B4838-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings: n6:271B4832-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge: n6:271B4831-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five: n6:271B4834-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name: n6:271B4822-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-: n6:271B482F-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-: n6:271B4830-363D-11E5-9242-09173F13E4C5